A multicenter clinical study of Ba qi ling mao formulation in the treatment of BCLC B / C stage of primary liver cancer

Shuguang Hospial Affiliated to Shanghai University of TCM0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. patients with primary liver cancer after radical resection (BCLC stage B, stage C);
•2. aged 18 to 70 years;
•3. The patients had not received systematic treatment before, including molecular targeted drug therapy, systemic chemotherapy, immunotherapy, etc;
•4. Patients who are unable or unwilling to accept surgery or have disease progression after local treatment and cannot be operated again;
•5. willing to accept Chinese medicine and/or integrated Chinese and western medicine treatment;
•6. sign informed consent.

•1. metastatic liver cancer patients, or concurrent with other cancer patients;
•2. Patients with refractory ascites, hepatic encephalopathy, hepatorenal syndrome and other serious complications;
•3. accompanied by heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract serious primary disease; Or mentally ill;
•4. legally disabled persons, pregnant women or nursing women;
•5. allergy or multiple drug allergy patients;
•6. Currently participating in other clinical trials.

发起方

Shuguang Hospial Affiliated to Shanghai University of TCM